Correction to: Monitoring of intracerebellarly-administered natural killer cells with fluorine-19 MRI

Kennis, Bridget; Michel, Keith A.; Brugmann, William; Laureano, Álvaro Macedo; Tao, Rong; Somanchi, Srinivas S.; Einstein, Samuel A.; Bravo-Alegría, Javiera; Maegawa, Satoru; Wahba, Andrew; Kiany, Simin; Gordon, Nancy; Silla, Lúcia Mariano da Rocha; Schellingerhout, Dawid; Khatua, Soumen; Zaky, Wafik; Sandberg, David I.; Cooper, Laurence J.N.; Lee, Dean A.; Bankson, James A.; Gopalakrishnan, Vidya

doi:10.1007/s11060-019-03162-7

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Natural Killer (NK) cells have emerged as a promising immunestrategy for hematological malignancies and solid tumors thanks to their capacity to lyse directly specific ligandtargeted cancer cells [180][181][182]. In the treatment of MB, one of the advantages of using NK cells is that this tumor shows the down-regulation of MHC-I that renders malignant cells more susceptible to NK cells-mediated lytic activity [183]. In addition, MB cells express ligands for triggering NK cells receptors and are sensitive to NK-mediated cytotoxicity in vitro [184,185].…”

Section: Natural Killermentioning

confidence: 99%

“…In particular, human DAOY MB cells express high levels of NKG2D, a NK-activating receptor that plays a major role in the killing of this tumor cell line [184]. Recently, in vivo studies demonstrated that the intratumor injection of activated NK cells suppresses the tumor growth of DAOY cells implanted into the cerebella of NSG mice [183]. A phase I trial is currently ongoing (NCT02271711) for the study of autologous NK cells delivered via the fourth ventricle catheter after surgery in patients with recurrent MB Table 2.…”

Section: Natural Killermentioning

confidence: 99%

See 1 more Smart Citation

The SHH/GLI signaling pathway: a therapeutic target for medulloblastoma

Severini

Ghirga

Bufalieri

et al. 2020

Expert Opinion on Therapeutic Targets

View full text Add to dashboard Cite

Introduction: Medulloblastoma (MB) is a heterogeneous tumor of the cerebellum that is divided into four main subgroups with distinct molecular and clinical features. Sonic Hedgehog MB (SHH-MB) is the most genetically understood and occurs predominantly in childhood. Current therapies consist of aggressive and non-targeted multimodal approaches that are often ineffective and cause long-term complications. These problems intensify the need to develop molecularly targeted therapies to improve outcome and reduce treatment-related morbidities. In this scenario, Hedgehog (HH) signaling, a developmental pathway whose deregulation is involved in the pathogenesis of several malignancies, has emerged as an attractive druggable pathway for SHH-MB therapy. Areas covered: This review provides an overview of the advancements in the HH antagonist research field. We place an emphasis on Smoothened (SMO) and glioma-associated oncogene homolog (GLI) inhibitors and immunotherapy approaches that are validated in preclinical SHH-MB models and that have therapeutic potential for MB patients. Literature from Pubmed and data reported on ClinicalTrial. gov up to August 2020 were considered. Expert opinion: Extensive-omics analysis has enhanced our knowledge and has transformed the way that MB is studied and managed. The clinical use of SMO antagonists has yet to be determined, however, future GLI inhibitors and multitargeting approaches are promising.

show abstract